COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #74 of 237
6/29 Late treatment study
Sosa-GarcĂ­a et al., Cir Cir. 2020, 88:5, 569-575, doi:10.24875/CIRU.20000675 (Peer Reviewed)
Experience in the management of severe COVID-19 patients in an intensive care unit
Source   PDF   Share   Tweet
Small retrospective study of 56 ICU patients in Mexico showing HCQ RR 1.1, p = 1.0.

Sosa et al., 6/29/2020, retrospective, Mexico, North America, peer-reviewed, baseline oxygen requirements 100.0%, 6 authors.
risk of death, 10.5% higher, RR 1.11, p = 1.00, treatment 7 of 38 (18.4%), control 3 of 18 (16.7%).
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit